EMA backs Onerji for advanced Parkinson disease with a positive CHMP opinion on continuous subcutaneous levodopa and carbidopa infusion

EMA CHMP issued a positive opinion for Onerji on 26 February 2026 in advanced Parkinson disease with uncontrolled motor fluctuations on oral therapy. Public primary documents confirm decision status, indication scope, and high-level benefit rationale, while trial-level comparative detail remains limited before European Commission decision and full SmPC release.